European Notebook: U.K. Early Access Scheme Starts; New HTA Body In Portugal; Doctors Oppose French Health Bill
Executive Summary
Merck’s Keytruda is made available before approval under U.K.’s new EAMS project; Portugal sets up a new technology assessment body, while Germany’s IQWIG says HTA dossiers could be a useful source of clinical trial data for other uses; in France, clinical trial lead times are lengthening and doctors protest a proposed reimbursement change.
You may also be interested in...
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Lifting the ‘Breakthrough’ Veil: FDA Increases Transparency To Reduce Futile Requests
Case studies demonstrating what kinds of drugs do and don’t qualify for the expedited pathway designation will be presented at an April workshop co-sponsored by the Brookings Institution.
Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.